141 related articles for article (PubMed ID: 34752187)
21. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
Corrias MV; Faulkner LB; Pistorio A; Rosanda C; Callea F; Piccolo MS; Scaruffi P; Marchi C; Lacitignola L; Occhino M; Gambini C; Tonini GP; Haupt R; De Bernardi B; Pistoia V; Garaventa A
Clin Cancer Res; 2004 Dec; 10(23):7978-85. PubMed ID: 15585633
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
23. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
[TBL] [Abstract][Full Text] [Related]
25. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
26. PHOX2B as a Reliable Marker for Neuroblastoma in Tissue and Cytology Specimens.
Ma Y; Feng J; Zhao J; Ding D; Tian F; Chen L; Zheng J; Xiao X
J Neuropathol Exp Neurol; 2021 Dec; 80(12):1108-1116. PubMed ID: 34965292
[TBL] [Abstract][Full Text] [Related]
27. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
29. Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.
Uemura S; Lin KS; Mon Thwin KK; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Mol Clin Oncol; 2021 Jul; 15(1):137. PubMed ID: 34055352
[TBL] [Abstract][Full Text] [Related]
30. Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration.
Grèze V; Brugnon F; Chambon F; Halle P; Canis M; Amiot C; Grémeau AS; Pereira B; Yáñez Peralta Y; Tchirkov A; Kanold J
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27734578
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of PHOX2B in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow.
Hata JL; Correa H; Krishnan C; Esbenshade AJ; Black JO; Chung DH; Mobley BC
Arch Pathol Lab Med; 2015 Apr; 139(4):543-6. PubMed ID: 25822764
[TBL] [Abstract][Full Text] [Related]
32. The Diagnostic Value of
Liu J; Li C; Yang X; Lu X; Zhang M; Qian L; Wang W; Kan Y; Yang J
Contrast Media Mol Imaging; 2022; 2022():7556315. PubMed ID: 35082556
[TBL] [Abstract][Full Text] [Related]
33. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
[TBL] [Abstract][Full Text] [Related]
34. The Application of and Factors Influencing, the NB5 Assay in Neuroblastomas.
Wang Z; Wang C; Xu Y; Le J; Jiang Y; Yao W; Wang H; Li K
Front Oncol; 2021; 11():633106. PubMed ID: 34055604
[TBL] [Abstract][Full Text] [Related]
35. RT-qPCR for
Grèze V; Kanold J; Chambon F; Halle P; Gremeau AS; Rives N; Rouel N; Pereira B; Tchirkov A; Brugnon F
Oncol Lett; 2017 Jul; 14(1):860-866. PubMed ID: 28693243
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons.
Reiff T; Tsarovina K; Majdazari A; Schmidt M; del Pino I; Rohrer H
J Neurosci; 2010 Jan; 30(3):905-15. PubMed ID: 20089899
[TBL] [Abstract][Full Text] [Related]
37. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
38. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
Fukuda M; Miyajima Y; Miyashita Y; Horibe K
J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
